<DOC>
	<DOCNO>NCT01030302</DOCNO>
	<brief_summary>The purpose study monitor factor past history , previous history drug use , degree response initial treatment , frequency previous therapy , age , Eastern Cooperative Oncology Group ( ECOG ) performance status , use doctor researcher assess patient 's disease progressing , assess disease affect daily live ability patient , determine appropriate treatment prognosis , bortezomib re-treatment , concomitant drug use re-treatment pattern treatment patient multiple myeloma re-treated injectable bortezomib .</brief_summary>
	<brief_title>A Retreatment Study With Bortezomib Multiple Myeloma</brief_title>
	<detailed_description>It essential obtain Korean clinical data efficacy safety re-treatment bortezomib well analyze actual pattern . The current trial prospective , multi-center , Phase 4 , observational study conduct collect demographic data past history , previous history drug use , degree response initial treatment , frequency previous therapy , age , Eastern Cooperative Oncology Group ( ECOG ) performance status , concomitant drug use re-treatment pattern treatment patient multiple myeloma re-treated injectable bortezomib . Also safety data collect . Observational Study -No investigational drug administer</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients multiple myeloma Patients treat bortezomib monotherapy bortezomib combination therapy Patients relapse &gt; = six month interval since last dose bortezomib Patients treatment response high partial remission ( PR ) previous bortezomib therapy Patients fully aware objective essential procedure current trial submit write informed consent declare voluntarily participate current trial The current presence past history hypersensitivity bortezomib constituent Severe hepatic dysfunction ( AST ALT first use &gt; = x 5 upper normal ) Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Bortezomib retreatment</keyword>
	<keyword>Velcade</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Bortezomib</keyword>
</DOC>